People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Fact checked by Nick Blackmer Tirzepatide and semaglutide, the ingredients in popular weight loss drugs, can both cause side ...

Participants in a new study who used GLP-1 drugs had a much lower cancer risk than those who had bariatric surgery.

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...